IBA Signs Contract to Install a 70 MeV Cyclotron Dedicated to the Production of Radiopharmaceuticals in Russia

Louvain-la-Neuve, Belgium, July 2nd, 2014 - IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy and radiopharmacy solutions, today announces it has signed a contract with a significant upfront payment with the Centre for Development of Nuclear Medicine in Moscow, Russia, for the installation of its Cyclone®70. The installation of the system is worth between EUR 12 and 15 million to IBA.

This 70 MeV Cyclotron will be dedicated to the production of new generation medical isotopes used mainly in the diagnosis of severe diseases.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted to see the Centre for Development of Nuclear Medicine in Moscow investing in our Cyclone®70 enabling year-round production of isotopes used in the diagnosis of critical illnesses. This third Cyclone®70 order further demonstrates IBA’s market-leading expertise and success with high energy cyclotrons.”

“IBA was selected for its leading technology and unrivalled know-how in developing high energy 70 MeV cyclotrons,” said Alexander Khasin, CEO of the Centre for Development of Nuclear Medicine. “We can rely on IBA’s expertise to reach our objective to supply the world with medical isotopes for the diagnosis and treatment of critical illnesses.”

The Centre for Development of Nuclear Medicine is a Moscow based company, whose main business areas are the supply of medical isotopes and radiopharmaceuticals for domestic and export markets, as well as medical services in Russia. Although the project is focused on routine production of radiopharmaceuticals, it also opens up several research isotopes not widely available in the world.

www.cdnm.ru

-ENDS-

Notes for Editors

About Cyclone®70
The Cyclone®70 is a high energy and high current proton industrial cyclotron. It is derived from the first Cyclone®70XP multiparticles cyclotron developed by IBA and has been fully operational for radioisotope production and research in France (Arronax project, Nantes) since 2011. IBA has sold a second Cyclone®70 to Zevacor in the US in 2013. This order in Russia is the third contract for an IBA Cyclone®70.
For more info, please visit our website:
www.iba-cyclotron-solutions.com/products-cyclo/cyclone-70
About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA
Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
thomas.ralet@iba-group.com

Centre for Development of Nuclear Medicine
Vitaly Bedarev
Chief Development Officer
+7 495 966 18 28
v.bedarev@cdnm.ru

For media and investor enquiries:

Consilium Strategic Communications
Amber Bielecka, Mary-Jane Elliott, Matthew Neal, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
IBA@consilium-comms.com